- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06032494
Investigating Changes in Vital Signs in Neonates (Neo-vital)
Neo-vital: Investigating Changes in Vital Signs in Neonates
1 in 7 babies require neonatal care. During their time in hospital their vital signs (such as heart rate, breathing rate and oxygen saturation) are continuously monitored as part of standard care. Many factors lead to changes in vital signs, for example, medical procedures such as blood tests can result in brief increases in heart rate. Medication can also alter vital signs, either as an intended effect or as a side effect. However, different infants will respond in different ways to both procedures and medication. Predicting how an individual infant may respond could lead to better individualised care for infants. For example, using an infant's baseline vital signs to predict whether they will experience cardiorespiratory side effects from a particular drug could mean that doctors could choose an alternative safer treatment plan. To develop these predictive models, it is essential to first better understand how infants' vital signs are affected by different procedures and drugs, and how these effects are impacted by other factors such as infection, other pathologies, interaction between drugs and age.
Despite their routine use in hospital neonatal units, detailed electronic records of vital signs are often not recorded. Often, only major events or average values are stated on clinical records. Subtle changes in vital signs are therefore missed, and more complex analysis that may reveal important predictive features within the data is not possible. In this study the investigators will electronically record infant vital signs across longer time periods and during a variety of clinically-necessary procedures and administration of drugs, to explore how these impact vital signs and are altered by factors such as age and pathology. These will be compared with control procedures, such as a nappy change, or when the infant is resting in their cot or receiving skin-to-skin care.
Study Overview
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Caroline Hartley, PhD
- Phone Number: +44 1865 234537
- Email: caroline.hartley@paediatrics.ox.ac.uk
Study Locations
-
-
-
Oxford, United Kingdom, OX14 3XL
- Recruiting
- John Radcliffe Hospital
-
Contact:
- Caroline Hartley, PhD
- Phone Number: +44 1865 234537
- Email: caroline.hartley@paediatrics.ox.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Infants will be eligible to be included in the study if they are:
- Born to, or expected to be born to, a mother aged 16 or over
- Admitted to the Newborn Care Unit, John Radcliffe Hospital, or anticipated delivery of a baby who will require admittance to the Newborn Care Unit at birth
- Mother given informed written consent
Exclusion Criteria:
Infants will be ineligible if the following exclusion criteria applies:
• Known chromosomal abnormality or life-threatening congenital abnormality
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in heart rate following drug administration
Time Frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.
|
To characterise the change in heart rate in infants following drug administration in a wide range of commonly used drugs in neonatal care.
Drugs will only be administered as part of clinical care, no drugs are administered for research purposes
|
1 day after drug administration, compared with baseline of 1 day before drug administration.
|
|
Change in oxygen saturation following drug administration
Time Frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.
|
To characterise the change in oxygen saturation in infants following drug administration in a wide range of commonly used drugs in neonatal care.
Drugs will only be administered as part of clinical care, no drugs are administered for research purposes
|
1 day after drug administration, compared with baseline of 1 day before drug administration.
|
|
Change in respiratory rate following drug administration
Time Frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.
|
To characterise the change in heart rate in infants following drug administration in a wide range of commonly used drugs in neonatal care.
Drugs will only be administered as part of clinical care, no drugs are administered for research purposes
|
1 day after drug administration, compared with baseline of 1 day before drug administration.
|
|
Change in heart rate following procedures
Time Frame: 1 day after procedure, compared with baseline of 1 day before procedure.
|
To characterise the change in heart rate in infants in relation to procedures, including (but not limited to) intubation and extubation, LISA (less invasive surfactant administration), blood transfusion and acute medically-required painful procedures.
|
1 day after procedure, compared with baseline of 1 day before procedure.
|
|
Change in oxygen saturation following procedures
Time Frame: 1 day after procedure, compared with baseline of 1 day before procedure.
|
To characterise the change in oxygen saturation in infants in relation to procedures, including (but not limited to) intubation and extubation, LISA (less invasive surfactant administration), blood transfusion and acute medically-required painful procedures.
|
1 day after procedure, compared with baseline of 1 day before procedure.
|
|
Change in respiratory rate following procedures
Time Frame: 1 day after procedure, compared with baseline of 1 day before procedure.
|
To characterise the change in respiratory rate in infants in relation to procedures, including (but not limited to) intubation and extubation, LISA (less invasive surfactant administration), blood transfusion and acute medically-required painful procedures.
|
1 day after procedure, compared with baseline of 1 day before procedure.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Models of drug response
Time Frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.
|
Prediction of drug regimen requirements in individual infants from respiratory rate.
|
1 day after drug administration, compared with baseline of 1 day before drug administration.
|
|
Models of procedure response
Time Frame: 1 day after procedure, compared with baseline of 1 day before procedure.
|
Prediction of procedure outcome in individual infants (e.g.
extubation success) from respiratory rate
|
1 day after procedure, compared with baseline of 1 day before procedure.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PID16761
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infant
-
Société des Produits Nestlé (SPN)RecruitingInfant Development | Growth and Development | Infant Health | Infant Formula | Infant Nutritional Physiological PhenomenaSaudi Arabia
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Colorado... and other collaboratorsCompletedInfant Growth | Infant Gut Microbiome | Infant Body FatUnited States
-
Christiana Care Health ServicesCompletedInfant | Infant, Premature | Infant, Preterm | Infant, LateUnited States
-
University of ArizonaMead Johnson NutritionActive, not recruiting
-
Turku University HospitalRecruitingPreterm Infant Development | Preterm Infant HealthJapan, South Korea
-
University of ManitobaJohns Hopkins University; University Health Network, Toronto; University of California... and other collaboratorsActive, not recruitingMaternal Health | Infant Growth | Infant NutritionCanada
-
NestléCompletedInfant Formula | Infant Nutritional Physiological PhenomenaSaudi Arabia
-
Yeditepe UniversityCompletedInfant Behavior | Infant Development | Early Intervention | TemperamentTurkey
-
University of Southern CaliforniaCompletedInfant Conditions | Infant Development | Infant, Very Low Birth Weight | Infant, Small for Gestational Age | Infant,PrematureUnited States
-
Bandim Health ProjectUniversity of Southern DenmarkCompleted